TW202313577A - 新穎化合物 - Google Patents

新穎化合物 Download PDF

Info

Publication number
TW202313577A
TW202313577A TW111120574A TW111120574A TW202313577A TW 202313577 A TW202313577 A TW 202313577A TW 111120574 A TW111120574 A TW 111120574A TW 111120574 A TW111120574 A TW 111120574A TW 202313577 A TW202313577 A TW 202313577A
Authority
TW
Taiwan
Prior art keywords
methyl
amino
piperidinyl
phenol
tri
Prior art date
Application number
TW111120574A
Other languages
English (en)
Chinese (zh)
Inventor
莉亞 奧蕾莉 布什
渥夫甘 葛巴
喬治 雅克
史黛芬妮 凱瑟琳娜 梅斯
亞當 安吉利奎 佩特尼
克里斯俊 席尼德
珊卓 史戴樂
安德烈斯 麥可 托斯托夫
Original Assignee
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商赫孚孟拉羅股份公司 filed Critical 瑞士商赫孚孟拉羅股份公司
Publication of TW202313577A publication Critical patent/TW202313577A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW111120574A 2021-06-04 2022-06-02 新穎化合物 TW202313577A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP21177660.4 2021-06-04
EP21177660 2021-06-04
EP21188639 2021-07-30
EP21188639.5 2021-07-30
EP21215875.2 2021-12-20
EP21215875 2021-12-20

Publications (1)

Publication Number Publication Date
TW202313577A true TW202313577A (zh) 2023-04-01

Family

ID=82115763

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111120574A TW202313577A (zh) 2021-06-04 2022-06-02 新穎化合物

Country Status (16)

Country Link
US (3) US20240132471A1 (OSRAM)
EP (1) EP4347571B1 (OSRAM)
JP (2) JP7705963B2 (OSRAM)
KR (1) KR20240019083A (OSRAM)
AR (1) AR126053A1 (OSRAM)
AU (1) AU2022287224A1 (OSRAM)
BR (1) BR112023025318A2 (OSRAM)
CA (1) CA3216026A1 (OSRAM)
CL (1) CL2023003491A1 (OSRAM)
CO (1) CO2023016212A2 (OSRAM)
CR (1) CR20230566A (OSRAM)
IL (1) IL307201A (OSRAM)
MX (1) MX2023013998A (OSRAM)
PE (1) PE20240928A1 (OSRAM)
TW (1) TW202313577A (OSRAM)
WO (1) WO2022253936A1 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
BR112023022451A2 (pt) * 2021-04-28 2024-01-02 Astellas Pharma Inc Composto triazina substituído
BR112023025318A2 (pt) * 2021-06-04 2024-02-27 Hoffmann La Roche Derivados de triazina e seu uso no tratamento do câncer
CA3246797A1 (en) * 2022-01-07 2025-07-08 Transthera Sciences (Nanjing) , Inc. Nlrp3 inflammasome inhibitor and application thereof
US20260015353A1 (en) * 2022-07-21 2026-01-15 Hoffmann-La Roche Inc. Novel compounds
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
CN121045190A (zh) * 2022-11-04 2025-12-02 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
CR20250215A (es) * 2022-12-07 2025-06-26 Hoffmann La Roche Compuestos novedosos como moduladores de la inhibición de nlrp3
KR20250158072A (ko) * 2023-03-20 2025-11-05 인실리코 메디신 아이피 리미티드 Nlrp3 인플라마좀 억제제 및 이의 용도
KR20250162889A (ko) * 2023-03-23 2025-11-19 청두 제니타르 바이오메디컬 테크놀로지 컴퍼니 리미티드 트리아진계 화합물 및 이의 용도
TW202448448A (zh) * 2023-04-19 2024-12-16 瑞士商赫孚孟拉羅股份公司 新穎化合物
CR20250409A (es) * 2023-04-19 2025-10-30 Hoffmann La Roche Derivados de oxazolo[4,5-b]pirazina y oxazolo[4,5-b]piridina como inhibidores de nlpr3 para el tratamiento de, por ejemplo, enfermedades inflamatoria
EP4719599A1 (en) 2023-06-02 2026-04-08 Merck Sharp & Dohme LLC 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
CN121586712A (zh) * 2023-07-28 2026-02-27 豪夫迈·罗氏有限公司 新颖化合物
KR20250030934A (ko) * 2023-08-25 2025-03-05 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies
WO2025252772A1 (en) * 2024-06-06 2025-12-11 F. Hoffmann-La Roche Ag Triazine derivatives
WO2026046981A1 (en) 2024-08-28 2026-03-05 F. Hoffmann-La Roche Ag Solid forms of 5-[3-[[(3r)-1-ethyl-3-piperidyl]amino]-5-methyl-1,2,4-triazin-6-yl]-2,3- dihydrobenzofuran-4-ol

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102636383B1 (ko) * 2017-08-04 2024-02-14 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
TW201910316A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
PE20210050A1 (es) 2017-11-09 2021-01-08 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida
AU2019243048A1 (en) * 2018-03-27 2020-10-15 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
CN119320388A (zh) * 2019-02-04 2025-01-17 斯基霍克疗法公司 用于调节剪接的方法和组合物
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
JP7843705B2 (ja) 2020-01-22 2026-04-10 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Nlrp3モジュレーターとしてのスルホンイミドアミド化合物
ES3064621T3 (en) 2020-03-27 2026-04-27 Tenvie Therapeutics Inc Substituted pyridazine compound
US20240391895A1 (en) 2020-12-25 2024-11-28 Tuojie Biotech (Shanghai) Co., Ltd. Pyridazine-containing compound and medicinal use thereof
WO2022166890A1 (zh) 2021-02-08 2022-08-11 南京明德新药研发有限公司 取代的哒嗪苯酚类衍生物
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
BR112023022451A2 (pt) 2021-04-28 2024-01-02 Astellas Pharma Inc Composto triazina substituído
BR112023025318A2 (pt) * 2021-06-04 2024-02-27 Hoffmann La Roche Derivados de triazina e seu uso no tratamento do câncer
US20240294542A1 (en) 2021-06-05 2024-09-05 Transthera Sciences (Nanjing), Inc. Nlrp3 inflammasome inhibitor and application thereof
HRP20251513T1 (hr) 2021-07-02 2026-01-02 Astrazeneca Ab Inhibitori inflamasoma nlrp3
WO2023028536A1 (en) 2021-08-25 2023-03-02 Ptc Therapeutics, Inc. 1,2,4-triazine derivatives useful as inhibitors of nlrp3
WO2023066377A1 (zh) 2021-10-22 2023-04-27 索智生物科技(浙江)有限公司 一种含氮化合物、其制备方法及应用
CA3246797A1 (en) 2022-01-07 2025-07-08 Transthera Sciences (Nanjing) , Inc. Nlrp3 inflammasome inhibitor and application thereof
IL315842A (en) 2022-03-25 2024-11-01 Ventus Therapeutics U S Inc Pyrido-[4,3-D]pyridazine amine derivatives are useful as NLRP3 derivatives
TW202432551A (zh) 2022-10-26 2024-08-16 日商安斯泰來製藥股份有限公司 稠環嗒嗪衍生物
CN115621720A (zh) * 2022-10-27 2023-01-17 永道射频技术股份有限公司 一种应用于rfid读写器的全息超材料阵列天线
CN121045190A (zh) 2022-11-04 2025-12-02 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
JP2026503239A (ja) 2022-12-28 2026-01-28 アストラゼネカ・アクチエボラーグ Nlrp3インフラマソーム阻害剤
CN120435466A (zh) 2023-02-17 2025-08-05 成都赜灵生物医药科技有限公司 六元氮杂环类化合物及其用途

Also Published As

Publication number Publication date
US20240132471A1 (en) 2024-04-25
WO2022253936A1 (en) 2022-12-08
CO2023016212A2 (es) 2023-12-11
PE20240928A1 (es) 2024-04-30
EP4347571B1 (en) 2026-04-22
AU2022287224A1 (en) 2023-09-21
CA3216026A1 (en) 2022-12-08
KR20240019083A (ko) 2024-02-14
JP2024522494A (ja) 2024-06-21
BR112023025318A2 (pt) 2024-02-27
AR126053A1 (es) 2023-09-06
JP7705963B2 (ja) 2025-07-10
JP2025098157A (ja) 2025-07-01
MX2023013998A (es) 2023-12-11
CR20230566A (es) 2024-01-22
EP4347571A1 (en) 2024-04-10
US20250197370A1 (en) 2025-06-19
IL307201A (en) 2023-11-01
US12421209B2 (en) 2025-09-23
US20250276958A1 (en) 2025-09-04
CL2023003491A1 (es) 2024-05-24

Similar Documents

Publication Publication Date Title
US12421209B2 (en) Compounds
TW202334153A (zh) 新穎化合物
US20240208928A1 (en) Novel compounds
TW202330545A (zh) 新穎化合物
TW202327603A (zh) 新穎化合物
TW202434581A (zh) 新穎化合物
TW202428282A (zh) 新穎化合物
TW202440569A (zh) 新穎化合物
US20250353830A1 (en) Novel compounds
US20260015353A1 (en) Novel compounds
CN117460718A (zh) 三嗪衍生物及其在癌症的治疗中的用途
RU2861618C2 (ru) Триазиновые производные и их применение в лечении рака
HK40101872A (zh) 三嗪衍生物及其在癌症的治疗中的用途
EA052779B1 (ru) Триазиновые производные и их применение в лечении рака
HK40122993A (zh) Nlrp3的抑制剂
TW202448448A (zh) 新穎化合物
HK40111084A (zh) 杂环nlrp3抑制剂
HK40110709A (zh) 作为nlrp3的抑制剂的哒嗪衍生物